Search

Ovulatory disorders are common causes of amenorrhea, abnormal uterine bleeding and infertility and are frequent manifestations of polycystic ovary syndrome (PCOS). There are many potential causes and contributors to ovulatory dysfunction that challenge clinicians, trainees, educators, and those who perform basic, translational, clinical and epidemiological research. Similarly, therapeutic approaches to ovulatory dysfunction potentially involve a spectrum of lifestyle, psychological, medical and procedural interventions. Collaborative research, effective education and consistent clinical care remain challenged by the absence of a consensus comprehensive system for classification of these disorders. The existing and complex system, attributed to the World Health Organization (WHO), was developed more than three decades ago and did not consider more than 30 years of research into these disorders in addition to technical advances in imaging and endocrinology. This article describes the development of a new classification of ovulatory disorders performed under the aegis of the International Federation of Gynecology and Obstetrics (FIGO) and conducted using a rigorously applied Delphi process. The stakeholder organizations and individuals who participated in this process comprised specialty journals, experts at large, national, specialty obstetrical and gynecological societies, and informed lay representatives. After two face-to-face meetings and five Delphi rounds, the result is a three-level multi-tiered system. The system is applied after a preliminary assessment identifies the presence of an ovulatory disorder. The primary level of the system is based on an anatomic model (Hypothalamus, Pituitary, Ovary) that is completed with a separate category for PCOS. This core component of the system is easily remembered using the acronym HyPO-P. Each anatomic category is stratified in the second layer of the system to provide granularity for investigators, clinicians and trainees using the ‘GAIN-FIT-PIE’ mnemonic (Genetic, Autoimmune, Iatrogenic, Neoplasm; Functional, Infectious and Inflammatory, Trauma and Vascular; Physiological, Idiopathic, Endocrine). The tertiary level allows for specific diagnostic entities. It is anticipated that, if widely adopted, this system will facilitate education, clinical care and the design and interpretation of research in a fashion that better informs progress in this field. Integral to the deployment of this system is a periodic process of reevaluation and appropriate revision, reflecting an improved understanding of this collection of disorders.

International audience; Background: Social metacognition is still poorly understood in schizophrenia, particularly its neuropsychological basis and its impact on insight and medication adherence. We therefore quantified social metacognition as the agreement between objective and subjective mentalization and assessed its correlates in a sample of individuals with schizophrenia spectrum disorders.Methods: Participants consisted of 143 patients with schizophrenia or schizoaffective disorders who underwent a metacognitive version of a mentalization task, an extensive neuropsychological battery, and a clinical evaluation to assess their insight into illness and medication adherence. We studied potential interactions between confidence judgments and several neuropsychological and clinical variables on mentalization accuracy with mixed-effects multiple logistic regressions.Results:Confidence judgments were closely associated with mentalization accuracy, indicative of good social metacognition in this task. Working memory, visual memory, and reasoning and problem-solving were the three neuropsychological dimensions positively associated with metacognition. By contrast, the two measures of medication adherence were associated with poorer metacognition, whereas no association was found between metacognition and clinical insight. The multiple regression model showed a significant positive impact of better working memory, older age at onset, longer duration of hospitalization, and worse medication adherence on social metacognition.Conclusions: We discuss possible mechanisms underlying the apparent association between social metacognition and working memory. Adherence should be monitored when remediating social metacognition, and psychoeducation should be given to patients with a high level of awareness of their capacity to mentalize.

Bipolar disorders (BD) affect 1.06 to 1.57% of the population (Clemente et al., 2015) and are associated with cognitive impairment (Cipriani et al., 2017). It can be partly attributed to the cognitive adverse effects of psychiatric treatments (Baldez et al., 2021; Bourne et al., 2013; Roux et al., 2019) and more specifically, to their anticholinergic properties (Mintzer et al., 2003; Richardson et al., 1994; Ziad et al., 2018). The association between anticholinergic burden and cognition has been largely studied in elderly patients and in schizophrenia (Ang et al., 2017; Javelot et al., 2022) whereas it has only been characterized once in BD (Eum et al., 2017). Assessing the association between anticholinergic burden and cognition in BD could help prescription, especially since highly anticholinergic drugs are used more often now than in 1995 (Reinold et al., 2021; Sumukadas et al., 2014). However, there is no consensus according to which one scale is better than another. We aim to explore the association between the score in anticholinergic burden scales and cognitive impairment in BD to reliably evaluate this association and eventually validate a scale for practice use. Besides, we investigate the validity of anticholinergic burden scales to assess anticholinergic side-effects other than cognition.

Preregistration available on Prospero: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=188614

Schizophrenia spectrum disorders (SCZ) are associated with cognitive impairment (Schaefer et al., 2013) with a significant deficit in attention, learning, memory, executive functioning, and social cognition (Green et al., 2000). Cognitive impairment in SCZ can persist even with medication: while antipsychotics have heterogeneous effects on cognition in SCZ (Baldez et al., 2021), antiparkisonian agents have anticholinergic properties and have consistently been associated to poorer cognitive performance (Brébion et al., 2004; Mintzer et al., 2003; Ziad et al., 2018) and impaired functional capacity (Khan et al., 2021). In addition, reducing the use of antiparkisonian agents has been associated with better cognitive performance in SCZ (Desmarais et al., 2021). Other drugs prescribed in SCZ have anticholinergic properties such as some antipsychotics and antidepressants. To evaluate the anticholinergic properties of the treatment, Anticholinergic Burden Scales (ABS) have been designed. Most ABS were created for elderly patients, which are particularly at risk of developing anticholinergic side-effects (Lisibach et al., 2021). In SCZ, several ABS were tested and their scores were associated to cognitive impairment (Georgiou et al., 2021). However, there is no consensus according to which one ABS is better than another to assess anticholinergic cognitive burden in SCZ. In the present project, we aim to compare the association between anticholinergic burden measured by different ABS and cognitive performance in patients with SCZ to identify and eventually suggest an ABS for practice use.

Additional file 5.

Additional file 3.

Additional file 1.

Additional file 4.

Additional file 2.

Supplemental material, Supplemental_Material for Screening for cognitive deficits with the Evaluation of Cognitive Processes involved in Disability in Schizophrenia scale by Paul Roux, Mathieu Urbach, Sandrine Fonteneau, Fabrice Berna, Lore Brunel, Delphine Capdevielle, Isabelle Chereau, Julien Dubreucq, Catherine Faget-Agius, Guillaume Fond, Sylvain Leignier, Claire-Cécile Perier, Raphaëlle Richieri, Priscille Schneider, Franck Schürhoff, Anne Marie Tronche, Hanan Yazbek, Anna Zinetti-Bertschy, the FondaMental Advanced Centers of Expertise in Schizophrenia (FACE-SCZ) Collaborators, Christine Passerieux, Eric Brunet-Gouet

Supplemental material, Supplemental_Material for Screening for cognitive deficits with the Evaluation of Cognitive Processes involved in Disability in Schizophrenia scale by Paul Roux, Mathieu Urbach, Sandrine Fonteneau, Fabrice Berna, Lore Brunel, Delphine Capdevielle, Isabelle Chereau, Julien Dubreucq, Catherine Faget-Agius, Guillaume Fond, Sylvain Leignier, Claire-Cécile Perier, Raphaëlle Richieri, Priscille Schneider, Franck Schürhoff, Anne Marie Tronche, Hanan Yazbek, Anna Zinetti-Bertschy, the FondaMental Advanced Centers of Expertise in Schizophrenia (FACE-SCZ) Collaborators, Christine Passerieux, Eric Brunet-Gouet

Supplemental material, Suppl_Table_1 for Characterization of depressed bipolar patients with current suicidal ideation by Bénédicte Nobile, Jonathan Dubois, Bruno Aouizerate, Valerie Aubin, Joséphine Loftus, Frank Bellivier, Raoul Belzeaux, Caroline Dubertret, Sebastien Gard, Emmanuel Haffen, Raymund Schwan, Pierre-Michel Llorca, Christine Passerieux, Paul Roux, Mircea Polosan, Bruno Etain, Marion Leboyer, Philippe Courtet and Emilie Olié in Australian & New Zealand Journal of Psychiatry

It is difficult for airline crews to identify odors that cause expensive delays and unscheduled maintenance. The Pall Cabin Air Quality Sensor (CAQS) identifies the source of an odor by utilizing aerospace qualified microelectronics technology, enabling focused maintenance, increasing up-time and reducing cost., This paper is part of: "2017 International Aircraft Cabin Air Conference : Conference Proceedings". In: Journal of Health and Pollution, Vol. 9, No. 24 (Dec. 2019)

On occasion, engine related contamination is able to enter the aircraft cabin as part of the fresh air supply, this can result in reduced air quality and expensive delays and schedule disruptions. Pall Aerospace are developing a filtration system, Clean Air Technology (CAT) that will remove this contamination from the fresh air supply before it is able to reach the cabin or cockpit., This paper is part of: "2017 International Aircraft Cabin Air Conference : Conference Proceedings". In: Journal of Health and Pollution, Vol. 9, No. 24 (Dec. 2019)

Supplemental material, Supplemental_Material for Assessing metacognitive and help-seeking strategies in schizophrenia: design and psychometric validation of the Versailles Metacognitive Strategies Evaluation Questionnaire by Eric Brunet-Gouet, Mathieu Urbach, Veronica Ramos, Mickael Ehrminger, Bruno Aouizerate, Lore Brunel, Delphine Capdevielle, Isabelle Chereau, Caroline Dubertret, Julien Dubreucq, Guillaume Fond, Christophe Lançon, Sylvain Leignier, Jasmina Mallet, David Misdrahi, Sylvie Pires, Priscille Schneider, Franck Schürhoff, Hanan Yazbek, Anna Zinetti-Bertschy, Nadine Bazin, Christine Passerieux and Paul Roux in Clinical Rehabilitation

Supplemental material, Supplemental_Material for Screening for cognitive deficits with the Evaluation of Cognitive Processes involved in Disability in Schizophrenia scale by Paul Roux, Mathieu Urbach, Sandrine Fonteneau, Fabrice Berna, Lore Brunel, Delphine Capdevielle, Isabelle Chereau, Julien Dubreucq, Catherine Faget-Agius, Guillaume Fond, Sylvain Leignier, Claire-Cécile Perier, Raphaëlle Richieri, Priscille Schneider, Franck Schürhoff, Anne Marie Tronche, Hanan Yazbek, Anna Zinetti-Bertschy, the FondaMental Advanced Centers of Expertise in Schizophrenia (FACE-SCZ) Collaborators, Christine Passerieux, Eric Brunet-Gouet, M Andrianarisoa, B Aouizerate, N Bazin, F Berna, O Blanc, L Brunel, E Bulzacka, D Capdevielle, I Chereau-Boudet, G Chesnoy-Servanin, JM Danion, T D’Amato, A Deloge, C Delorme, H Denizot, JM Dorey, C Dubertret, J Dubreucq, C Faget, C Fluttaz, G Fond, S Fonteneau, F Gabayet, E Giraud-Baro, D Lacelle, C Lançon, H Laouamri, M Leboyer, T Le Gloahec, Y Le Strat, PM Llorca, J Mallet, E Metairie, D Misdrahi, I Offerlin-Meyer, C Passerieux, P Peri, S Pires, C Portalier, L Ramet, R Rey, C Roman, A Schandrin, F Schürhoff, A Tessier, AM Tronche, M Urbach, F Vaillant, A Vehier, P Vidailhet, E Vilà, H Yazbek and A Zinetti-Bertschy in Clinical Rehabilitation

Supplemental material, Supplementary_Informatiion_2 for Screening for cognitive deficits with the Evaluation of Cognitive Processes involved in Disability in Schizophrenia scale by Paul Roux, Mathieu Urbach, Sandrine Fonteneau, Fabrice Berna, Lore Brunel, Delphine Capdevielle, Isabelle Chereau, Julien Dubreucq, Catherine Faget-Agius, Guillaume Fond, Sylvain Leignier, Claire-Cécile Perier, Raphaëlle Richieri, Priscille Schneider, Franck Schürhoff, Anne Marie Tronche, Hanan Yazbek, Anna Zinetti-Bertschy, the FondaMental Advanced Centers of Expertise in Schizophrenia (FACE-SCZ) Collaborators, Christine Passerieux, Eric Brunet-Gouet, M Andrianarisoa, B Aouizerate, N Bazin, F Berna, O Blanc, L Brunel, E Bulzacka, D Capdevielle, I Chereau-Boudet, G Chesnoy-Servanin, JM Danion, T D’Amato, A Deloge, C Delorme, H Denizot, JM Dorey, C Dubertret, J Dubreucq, C Faget, C Fluttaz, G Fond, S Fonteneau, F Gabayet, E Giraud-Baro, D Lacelle, C Lançon, H Laouamri, M Leboyer, T Le Gloahec, Y Le Strat, PM Llorca, J Mallet, E Metairie, D Misdrahi, I Offerlin-Meyer, C Passerieux, P Peri, S Pires, C Portalier, L Ramet, R Rey, C Roman, A Schandrin, F Schürhoff, A Tessier, AM Tronche, M Urbach, F Vaillant, A Vehier, P Vidailhet, E Vilà, H Yazbek and A Zinetti-Bertschy in Clinical Rehabilitation

Supplemental material, Supplementary_Information_1 for Screening for cognitive deficits with the Evaluation of Cognitive Processes involved in Disability in Schizophrenia scale by Paul Roux, Mathieu Urbach, Sandrine Fonteneau, Fabrice Berna, Lore Brunel, Delphine Capdevielle, Isabelle Chereau, Julien Dubreucq, Catherine Faget-Agius, Guillaume Fond, Sylvain Leignier, Claire-Cécile Perier, Raphaëlle Richieri, Priscille Schneider, Franck Schürhoff, Anne Marie Tronche, Hanan Yazbek, Anna Zinetti-Bertschy, the FondaMental Advanced Centers of Expertise in Schizophrenia (FACE-SCZ) Collaborators, Christine Passerieux, Eric Brunet-Gouet, M Andrianarisoa, B Aouizerate, N Bazin, F Berna, O Blanc, L Brunel, E Bulzacka, D Capdevielle, I Chereau-Boudet, G Chesnoy-Servanin, JM Danion, T D’Amato, A Deloge, C Delorme, H Denizot, JM Dorey, C Dubertret, J Dubreucq, C Faget, C Fluttaz, G Fond, S Fonteneau, F Gabayet, E Giraud-Baro, D Lacelle, C Lançon, H Laouamri, M Leboyer, T Le Gloahec, Y Le Strat, PM Llorca, J Mallet, E Metairie, D Misdrahi, I Offerlin-Meyer, C Passerieux, P Peri, S Pires, C Portalier, L Ramet, R Rey, C Roman, A Schandrin, F Schürhoff, A Tessier, AM Tronche, M Urbach, F Vaillant, A Vehier, P Vidailhet, E Vilà, H Yazbek and A Zinetti-Bertschy in Clinical Rehabilitation

There is mounting evidence that Volatile Organic Compounds (VOCs) and other aerosolised condensates and vapours related to contamination of breathing air in modern aircraft could have health and safety implications for both the passengers and the air crew. This presentation provides a review of the technologies currently available for aircraft cabin air treatment; disposable carbon adsorbent filters, photocatalytic oxidation, catalytic converters and non-thermal plasma oxidation. It explains the basic principles of each existing technology and then focuses on the Pall Photocatalytic Regenerable Adsorption (PCRA) system. The PCRA system uses a unique combination of adsorbent and catalyst technologies to remove particulate and gaseous contamination from the cabin air supply. I. Introduction his paper focuses on the technologies that can be installed for the treatment of the cabin air supply on commercial and military aircraft. In modern aircraft the air in the cabin is provided by the environmental control system (ECS) which is designed to control the cabin pressure, cabin temperature, maintain air quality and filter/dissipate any particulate matter, smoke and odours that are present in the cabin 1 . In a typical commercial cabin air recirculation system, the air supplied into the cabin consists of approximately 50% outside air from either the engine’s compressor stage (engine ‘bleed air’) or the Auxiliary Power Unit (APU) which is mixed with approximately 50% of filtered, recirculated air. (Note however, that some aircraft designs are now moving to ‘bleed air free’ ECS). Cabin air particulate filters are normally located in the recirculation loop and these are usually rated at 99.99% sodium flame test efficiency or the equivalent 99.97% D.O.P. (Di-Octyl Phthalate) efficiency. In certain cases a lower level of filtration may be in use, but generally there is an option of upgrading to HEPA filtration (equal to or greater than EU grade H13 2 ). Filters manufactured to this ‘true HEPA’ specification provide excellent standards of particulate contaminant removal and control of micro-organisms from the recirculated cabin air 3 . However, some particulate contamination, odour causing compounds and volatile and semi-volatile organic compounds (VOCs and SVOCs) may enter from the outside air system where filtration is not normally provided. In order to provide a safe, healthy and comfortable environment for the passengers and crew, consideration needs to be given to providing adequate purification of both the outside air (‘bleed air’), as well as the recirculated air, for both existing and future aircraft designs.

n/a